Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug ...

In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

The National Association of Experts in the Field of Primary Immunodeficiencies shared the results of a study evaluating the effectiveness of subcutaneous immunoglobulin administration in patients with ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo ... The Vyvgart Hytrulo ...

This wearable delivery system enables large-volume, high-viscosity subcutaneous drug administration in either clinical settings or home self-administration.” Cincinnati-based Enable Injections ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients with generalized myasthenia gravis.

Hooven, Chairman and CEO of Enable Injections. "Our enFuse platform is uniquely positioned to address challenges in developing large-volume subcutaneous oncology drugs. This wearable delivery system ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by ... original IV formulations improves the ease of administration for the drugs, reducing the time ...

Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As ...